Sodium Accumulation Study in Haemodialysis: Brain Study (SASH-B)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05966116 |
Recruitment Status :
Not yet recruiting
First Posted : July 28, 2023
Last Update Posted : February 23, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Dialysis; Complications |
Haemodialysis (HD) sustains life in patients with end-stage kidney disease (ESKD) but is associated with a marked increase in cognitive impairment, being three times more common and presenting at a younger age. The predominant features of cognitive impairment associated with HD are loss of executive function, including higher processing such as planning, task prioritisation and self-regulation. The mechanism for development and acceleration of cognitive impairment on dialysis is not well understood, however hypertension and cardiovascular disease are likely to play a significant role, alongside changes in brain perfusion as a result of dialysis itself, which has been shown in a prior study using PET-CT.
Sodium balance is normally regulated by the kidneys in health, but has to be achieved by sodium removal during HD for those with ESKD. Recent evidence suggests that accumulation of sodium in tissue may be a critical factor impacting the development of hypertension and cardiovascular disease (CVD) in patients with ESKD. Non-invasive methods are therefore required to study tissue sodium accumulation in this context.
23Na MRI has the potential to provide complementary quantitative parameters of tissue health, in a non-invasive manner. Sodium homeostasis is central to maintenance of human physiology, providing an index of cellular integrity and energy status. The maintenance of sodium gradients across the cell membrane, by the Na+/K+ ATPase pump, enables 23Na MRI to distinguish between different environments within organs, providing a biomarker of disease status, notably kidney disease, hypertension, and brain disorders.
Previously, traditional proton (1H) magnetic resonance imaging (MRI) in dialysis patients demonstrated a decrease in grey matter T1 and an accompanying increase in white matter T1 when comparing scans before, during and after dialysis, In this context, T1 can be thought of as a marker of water content. This demonstrates that changes in the brain occur as a direct consequence of dialysis, with fluid and sodium shifts across cellular compartments the most likely explanation. This is important, as it suggests a novel mechanism by which dialysis may cause reductions in cognitive function. However, this needs further study to establish these mechanisms with more confidence.
At the SPMIC, a dual tuned proton(1H)/sodium(23Na) volume head RF coil for 23Na imaging of the brain has been installed and interfaced; and imaging methods to perform 23Na MRI of the brain have been optimised.
This study proposes to utilise 23Na MRI of the brain along with proton measures of T1, before and after dialysis within existing experimental set-up at SPMIC. This will provide new insights into the direct effects of dialysis on brain sodium levels, and in turn deepen our understanding of the link between sodium, fluid overload, dialysis and the brain.
Study Type : | Observational |
Estimated Enrollment : | 10 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Sodium Accumulation Study in Haemodialysis: Brain Study |
Estimated Study Start Date : | March 2024 |
Estimated Primary Completion Date : | February 2025 |
Estimated Study Completion Date : | February 2025 |
- Proportion of brain images that can be analysed for sodium levels [ Time Frame: 12 months ]success criterion > 85%
- Change in grey and white matter sodium levels [ Time Frame: 12 months ]comparing before and after dialysis
- Association between change in brain sodium levels to proton MRI measures [ Time Frame: 12 months ]grey/white matter volume, T1
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age 50-75 years inclusive
- Male and female patients with CKD stage 5 receiving chronic haemodialysis
- Patient has been dialysis dependent for at least 3 months
- Must be able to follow simple instruction in English (on safety ground for MRI scans) and be able to understand the nature and requirements of the study
Exclusion Criteria:
- Active infection or malignancy
- Amputee
- Pregnancy
- Contraindication to MRI scanning including claustrophobia, pacemaker, metallic implants etc
- Unable or unwilling to provide informed consent
- Medical conditions or overall physical frailty precludes scan session in opinion of investigator
- Any condition which could interfere with the patient's ability to comply with the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05966116
Contact: Rebecca A Noble, BMBS | 01332340131 ext 88262 | rebecca.noble1@nottingham.ac.uk |
United Kingdom | |
Centre for Kidney Research and Innovation | |
Derby, United Kingdom, DE22 3NE | |
Contact: Rebecca A Noble, BMBS rebecca.noble1@nottingham.ac.uk |
Principal Investigator: | Rebecca A Noble, BMBS | The University of Nottingham |
Responsible Party: | University Hospitals of Derby and Burton NHS Foundation Trust |
ClinicalTrials.gov Identifier: | NCT05966116 |
Other Study ID Numbers: |
UHDB/2023/055 |
First Posted: | July 28, 2023 Key Record Dates |
Last Update Posted: | February 23, 2024 |
Last Verified: | February 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |